Screener
Gyre Therapeutics, Inc. GYRE Gain (loss) on disposal of assets
Discontinued — last reported Q4 '25
Gain (loss) on disposal of assets at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.
The source filing: Gyre Therapeutics, Inc.’s 10-K, filed March 13, 2026.
- Filed
- Mar 13, 2026, 4:31 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-106251
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Selling and marketing | 65,179 | 57,511 |
| Research and development | 13,698 | 12,024 |
| General and administrative | 20,804 | 16,109 |
| Loss on disposal of assets, net | 4 | 66 |
| Total operating expenses | 105,101 | 89,594 |
| Income from operations | 11,487 | 16,163 |
| Other income (expenses): | ||
| Interest income, net | 1,747 | 1,547 |
Item 16.
FAQ
- What is Gyre Therapeutics, Inc.'s gain (loss) on disposal of assets?
- Gyre Therapeutics, Inc. (GYRE) reported gain (loss) on disposal of assets of -$2K in Q4 2025.
- What does gain (loss) on disposal of assets mean?
- Gains or losses recognized on the disposal of businesses, property, equipment, investments, or other assets at prices above or below their carrying value.
Ask your AI about Gyre Therapeutics, Inc.'s gain (loss) on disposal of assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude